

2019 Future of Scar R&D Pipeline Drugs and Companies- Analysis of Global Scar Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/24DFFA636EFEN.html>

Date: January 2019

Pages: 75

Price: US\$ 2,199.00 (Single User License)

ID: 24DFFA636EFEN

Abstracts

The global demand for Scar treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Scar pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Scar pipeline companies from advancing their products into Phase 3 or Phase 4.

Scar Report Description

The H1 2019 pipeline review report on Scar pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Scar pipeline compounds.

The Scar pipeline guide presents information on all active drugs currently being developed for Scar. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Scar pipeline

candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Scar drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Scar product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Scar pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Scar pipeline report includes

An overview of Scar disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator,

Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Scar pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Scar pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Scar pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL SCAR PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Scar Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Scar pipeline, H1- 2019
- 3.5 Mechanism of Action wise Scar Pipeline Candidates

4. ADE THERAPEUTICS INC SCAR PIPELINE DETAILS

- 4.1 AdeTherapeutics Inc Business Profile
- 4.2 AdeTherapeutics Inc Scar Drug Details
 - 4.2.1 Drug Snapshot
 - 4.2.1.1 Originator
 - 4.2.1.2 Collaborator/Co-Developer
 - 4.2.1.3 Route of Administration
 - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 4.2.1.5 Area
 - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5. ALTACOR LTD SCAR PIPELINE DETAILS

- 5.1 Altacor Ltd Business Profile
- 5.2 Altacor Ltd Scar Drug Details
 - 5.2.1 Drug Snapshot
 - 5.2.1.1 Originator
 - 5.2.1.2 Collaborator/Co-Developer
 - 5.2.1.3 Route of Administration
 - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 5.2.1.5 Area
 - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6. BIRCHBIOMED INC SCAR PIPELINE DETAILS

- 6.1 BirchBioMed Inc Business Profile
- 6.2 BirchBioMed Inc Scar Drug Details
 - 6.2.1 Drug Snapshot
 - 6.2.1.1 Originator
 - 6.2.1.2 Collaborator/Co-Developer
 - 6.2.1.3 Route of Administration
 - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 6.2.1.5 Area
 - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7. COTINGA PHARMACEUTICALS INC SCAR PIPELINE DETAILS

- 7.1 Cotinga Pharmaceuticals Inc Business Profile
- 7.2 Cotinga Pharmaceuticals Inc Scar Drug Details
 - 7.2.1 Drug Snapshot

- 7.2.1.1 Originator
- 7.2.1.2 Collaborator/Co-Developer
- 7.2.1.3 Route of Administration
- 7.2.1.4 Orphan Drug/Fast Track/Special Designation
- 7.2.1.5 Area
- 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8. EMBER THERAPEUTICS INC SCAR PIPELINE DETAILS

- 8.1 Ember Therapeutics Inc Business Profile
- 8.2 Ember Therapeutics Inc Scar Drug Details
 - 8.2.1 Drug Snapshot
 - 8.2.1.1 Originator
 - 8.2.1.2 Collaborator/Co-Developer
 - 8.2.1.3 Route of Administration
 - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 8.2.1.5 Area
 - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9. KRINGLE PHARMA INC SCAR PIPELINE DETAILS

- 9.1 Kringle Pharma Inc Business Profile
- 9.2 Kringle Pharma Inc Scar Drug Details
 - 9.2.1 Drug Snapshot
 - 9.2.1.1 Originator
 - 9.2.1.2 Collaborator/Co-Developer
 - 9.2.1.3 Route of Administration
 - 9.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 9.2.1.5 Area

- 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10. MOERAE MATRIX INC SCAR PIPELINE DETAILS

- 10.1 Moerae Matrix Inc Business Profile
- 10.2 Moerae Matrix Inc Scar Drug Details
 - 10.2.1 Drug Snapshot
 - 10.2.1.1 Originator
 - 10.2.1.2 Collaborator/Co-Developer
 - 10.2.1.3 Route of Administration
 - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 10.2.1.5 Area
 - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11. PHARMAXIS LTD SCAR PIPELINE DETAILS

- 11.1 Pharmaxis Ltd Business Profile
- 11.2 Pharmaxis Ltd Scar Drug Details
 - 11.2.1 Drug Snapshot
 - 11.2.1.1 Originator
 - 11.2.1.2 Collaborator/Co-Developer
 - 11.2.1.3 Route of Administration
 - 11.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 11.2.1.5 Area
 - 11.2.1.6 Type of Molecular Entity
- 11.3 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details

11.7 Latest Drug Developments

12. PROMORE PHARMA AB SCAR PIPELINE DETAILS

12.1 Promore Pharma AB Business Profile

12.2 Promore Pharma AB Scar Drug Details

12.2.1 Drug Snapshot

12.2.1.1 Originator

12.2.1.2 Collaborator/Co-Developer

12.2.1.3 Route of Administration

12.2.1.4 Orphan Drug/Fast Track/Special Designation

12.2.1.5 Area

12.2.1.6 Type of Molecular Entity

12.3 Current Status

12.4 Drug Overview

12.5 Drug Mechanism of Action

12.6 Clinical/Pre-clinical Trial Details

12.7 Latest Drug Developments

13. RESOLYS BIO INC SCAR PIPELINE DETAILS

13.1 Resolys Bio Inc Business Profile

13.2 Resolys Bio Inc Scar Drug Details

13.2.1 Drug Snapshot

13.2.1.1 Originator

13.2.1.2 Collaborator/Co-Developer

13.2.1.3 Route of Administration

13.2.1.4 Orphan Drug/Fast Track/Special Designation

13.2.1.5 Area

13.2.1.6 Type of Molecular Entity

13.3 Current Status

13.4 Drug Overview

13.5 Drug Mechanism of Action

13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14. RXI PHARMACEUTICALS CORP SCAR PIPELINE DETAILS

14.1 RXi Pharmaceuticals Corp Business Profile

14.2 RXi Pharmaceuticals Corp Scar Drug Details

14.2.1 Drug Snapshot

14.2.1.1 Originator

14.2.1.2 Collaborator/Co-Developer

14.2.1.3 Route of Administration

14.2.1.4 Orphan Drug/Fast Track/Special Designation

14.2.1.5 Area

14.2.1.6 Type of Molecular Entity

14.3 Current Status

14.4 Drug Overview

14.5 Drug Mechanism of Action

14.6 Clinical/Pre-clinical Trial Details

14.7 Latest Drug Developments

15. SCARX THERAPEUTICS SCAR PIPELINE DETAILS

15.1 ScarX Therapeutics Business Profile

15.2 ScarX Therapeutics Scar Drug Details

15.2.1 Drug Snapshot

15.2.1.1 Originator

15.2.1.2 Collaborator/Co-Developer

15.2.1.3 Route of Administration

15.2.1.4 Orphan Drug/Fast Track/Special Designation

15.2.1.5 Area

15.2.1.6 Type of Molecular Entity

15.3 Current Status

15.4 Drug Overview

15.5 Drug Mechanism of Action

15.6 Clinical/Pre-clinical Trial Details

15.7 Latest Drug Developments

16. SYNEDGEN INC SCAR PIPELINE DETAILS

16.1 Synedgen Inc Business Profile

16.2 Synedgen Inc Scar Drug Details

16.2.1 Drug Snapshot

16.2.1.1 Originator

16.2.1.2 Collaborator/Co-Developer

16.2.1.3 Route of Administration

16.2.1.4 Orphan Drug/Fast Track/Special Designation

16.2.1.5 Area

16.2.1.6 Type of Molecular Entity

16.3 Current Status

16.4 Drug Overview

16.5 Drug Mechanism of Action

16.6 Clinical/Pre-clinical Trial Details

16.7 Latest Drug Developments

17. VASCULAR BIOSCIENCES SCAR PIPELINE DETAILS

17.1 Vascular BioSciences Business Profile

17.2 Vascular BioSciences Scar Drug Details

17.2.1 Drug Snapshot

17.2.1.1 Originator

17.2.1.2 Collaborator/Co-Developer

17.2.1.3 Route of Administration

17.2.1.4 Orphan Drug/Fast Track/Special Designation

17.2.1.5 Area

17.2.1.6 Type of Molecular Entity

17.3 Current Status

17.4 Drug Overview

17.5 Drug Mechanism of Action

17.6 Clinical/Pre-clinical Trial Details

17.7 Latest Drug Developments

18. LATEST SCAR DRUG PIPELINE DEVELOPMENTS, 2019

19. APPENDIX

19.1 About Us

19.2 Sources and Methodology

19.3 Contact Information

I would like to order

Product name: 2019 Future of Scar R&D Pipeline Drugs and Companies- Analysis of Global Scar Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/24DFFA636EFEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/24DFFA636EFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

